Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Pharvaris has a consensus analyst rating of Moderate Buy from 13 firms (10 buys, 2 holds, 1 sell) and an average 1‑year price target of $41.60.
• Shares opened at $28.37, trading near their 52‑week high of $29.85, with a market cap of $1.54 billion and a negative P/E of -8.42.
• Pharvaris is a clinical‑stage biopharma focused on hereditary angioedema; its lead candidate, PHA121, is an oral plasma kallikrein inhibitor progressing through prophylactic clinical trials.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $41.60.

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research report on Thursday, January 22nd. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Pharvaris in a research report on Tuesday, March 3rd. Wall Street Zen lowered shares of Pharvaris from a "hold" rating to a "sell" rating in a research report on Sunday. Finally, Royal Bank Of Canada lowered their price target on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating on the stock in a research report on Monday.

Pharvaris Stock Down 0.7%

Shares of NASDAQ PHVS opened at $28.37 on Tuesday. The company's 50-day simple moving average is $27.07 and its 200-day simple moving average is $25.47. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.85. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -8.42 and a beta of -2.58.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of PHVS. Geode Capital Management LLC boosted its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock worth $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc boosted its position in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi boosted its position in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company's stock worth $489,000 after acquiring an additional 27,416 shares during the last quarter. Finally, HighVista Strategies LLC boosted its position in Pharvaris by 4.3% during the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company's stock worth $418,000 after acquiring an additional 971 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.